1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,911 | 0,944 | 09:40 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 51,72 | +0,27 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 272,10 | -1,09 % | EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) | ||
| ARBUTUS BIOPHARMA | 3,466 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| VERICEL | 30,400 | +1,33 % | Vericel Corporation: Vericel Announces Preliminary 2025 Financial Results and Business Updates | Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,230 | -0,47 % | Moleculin Biotech, Inc.: Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects | - Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials - This next-generation anthracycline demonstrates safety and promising early activity in treating multiple... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,570 | -0,93 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,425 | -11,64 % | BioTech und LifeSciences stark im Aufwind und nun auch noch Mercosur! Bayer, MustGrow, Novo Nordisk und BioNxt im Fokus | Das Börsenjahr 2026 hält für die Anleger einige Überraschungen parat. Denn neben einer schnellen Lösung im Grönland-Streit, macht sich auch das Handelsabkommen Mercosur mit einigen Südamerika-Staaten... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,294 | -3,29 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| REGENXBIO | 9,400 | -0,53 % | Regenerative Medizin im Aufschwung: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Strategien | ||
| AKEBIA | 1,181 | -1,09 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| ZEVRA THERAPEUTICS | 7,550 | -0,66 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,300 | 0,00 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | - City of Hope to Evaluate PEDMARK- for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors - - Initiation of Study Reflects Growing Clinical Interest in Addressing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 17,680 | +1,26 % | If You Invested $1000 In Corvus Pharma Stock 5 Years Ago, You Would Have This Much Today | ||
| CARTESIAN THERAPEUTICS | 5,450 | -6,03 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| NANOBIOTIX | 17,280 | -0,23 % | Nanobiotix S.A.: NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris | PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen |
Das Unternehmen SYNTHAVERSE SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,39 % bei einem Aktienkurs von 0,924 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.